2-Chloro-3-hydroxy-4-methoxybenzoic acid | 87277-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Chloro-3-hydroxy-4-methoxybenzoic acid
• CAS: 87277-06-3
• 化学式: C₈H₇ClO₄
• 分子量: 202.59
• InChiKey: QVZPIEIMRVXFFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Process for the degradation of enviromentally persistent organic compounds
  申请人：Utah State University Foundation

  公开号：EP0192237A1

  公开（公告）日：1986-08-27

  A process is described for degrading organic pollutant compounds using fungal enzymes containing a lignin degrading enzyme using hydrogen peroxide. The process particularly uses Phanerochaete chrysosporium as a source of the hydrogen peroxide and the enzymes. The process is particularly useful for degrading halogenated hydrocarbons with the halogens substituted in bicyclic rings, which are resistant to biodegradation and which occur in the environment as persistent pollutants.

  描述了一种利用含有木质素降解酶的真菌酶使用过氧化氢降解有机污染物化合物的工艺。该工艺特别使用 Phanerochaete chrysosporium 作为过氧化氢和酶的来源。该工艺特别适用于降解卤素取代了双环的卤代烃，这些卤代烃对生物降解有抵抗力，而且作为持久性污染物存在于环境中。
• US6420365B1
  申请人：——

  公开号：US6420365B1

  公开（公告）日：2002-07-16
• [EN] IMIDAZOPYRIDINES AND RELATED AZACYCLIC DERIVATIVES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS<br/>[FR] IMIDAZOPYRIDINES ET DERIVES AZACYCLIQUES CONNEXES EN TANT QUE MODULATEURS SELECTIFS DE RECEPTEURS B2 DE LA BRADYKININE
  申请人：NEUROGEN CORP

  公开号：WO2001053298A1

  公开（公告）日：2001-07-26

  Disclosed are compounds of formula (I) or the pharmaceutically acceptable non-toxic salts thereof wherein A, B, C, D, Y, R1, R3, R4, R5, and R6 are variables defined herein, which compounds are modulators of Bradykinin B2 receptors. These compounds are useful in the diagnosis and treatment of renal diseases, heart failure, hypertension, Meniere's disease, vaginal inflammation and pain, peripheral circulatory disorders, climacteric disturbance, retinochoroidal circulatory disorders, myocardial ischemia, myocardial infarction, postmyocardial infarction syndrome, angina pectoris, restenosis after percutaneous transluminal coronary angioplasty, hepatitis, liver cirrhosis, pancreatitis, ileus, diabetes, diabetic complications, male infertility, glaucoma, pain, asthema, and rhinitis and for the increase of permeability of the blood-brain barrier or the blood-brain-tumor barrier.